NCT00544440View on ClinicalTrials.gov

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Prostate Neoplasms
Interventions
DRUG

Abiraterone acetate

Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily

DRUG

Prednisone

Prednisone 5 mg tablet taken orally twice daily

Trial Locations (1)

Unknown

Houston

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT00544440 - An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma | Biotech Hunter | Biotech Hunter